These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28837822)

  • 1. Tumor-homing, pH- and ultrasound-responsive polypeptide-doxorubicin nanoconjugates overcome doxorubicin resistance in cancer therapy.
    Wang Z; He Q; Zhao W; Luo J; Gao W
    J Control Release; 2017 Oct; 264():66-75. PubMed ID: 28837822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
    Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
    J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of tumor-homing and pH-responsive polypeptide-doxorubicin nanoparticles with enhanced anticancer efficacy and reduced side effects.
    Hu J; Xie L; Zhao W; Sun M; Liu X; Gao W
    Chem Commun (Camb); 2015 Jul; 51(57):11405-8. PubMed ID: 26086450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
    Braunová A; Kostka L; Sivák L; Cuchalová L; Hvězdová Z; Laga R; Filippov S; Černoch P; Pechar M; Janoušková O; Šírová M; Etrych T
    J Control Release; 2017 Jan; 245():41-51. PubMed ID: 27871991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
    Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
    Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular structural transformation regulated dynamic disordering of supramolecular vesicles as pH-responsive drug release systems.
    Liu Y; Gao FP; Zhang D; Fan YS; Chen XG; Wang H
    J Control Release; 2014 Jan; 173():140-7. PubMed ID: 24188958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin-inspired vehicles based on pH-responsive coordination bond to combat multidrug-resistant breast cancer.
    He YJ; Xing L; Cui PF; Zhang JL; Zhu Y; Qiao JB; Lyu JY; Zhang M; Luo CQ; Zhou YX; Lu N; Jiang HL
    Biomaterials; 2017 Jan; 113():266-278. PubMed ID: 27842254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneously overcome tumor vascular endothelium and extracellular matrix barriers via a non-destructive size-controlled nanomedicine.
    Wang B; Zhai Y; Shi J; Zhuang L; Liu W; Zhang H; Zhang H; Zhang Z
    J Control Release; 2017 Dec; 268():225-236. PubMed ID: 29054372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer.
    Dong D; Gao W; Liu Y; Qi XR
    Cancer Lett; 2015 Apr; 359(2):178-86. PubMed ID: 25592040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.
    Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J
    Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An imaging-guided platform for synergistic photodynamic/photothermal/chemo-therapy with pH/temperature-responsive drug release.
    Lv R; Yang P; He F; Gai S; Yang G; Dai Y; Hou Z; Lin J
    Biomaterials; 2015 Sep; 63():115-27. PubMed ID: 26093792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
    Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
    Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy.
    Mou Q; Ma Y; Zhu X; Yan D
    J Control Release; 2016 May; 230():34-44. PubMed ID: 27040815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
    Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
    Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The release of Doxorubicin from liposomes monitored by MRI and triggered by a combination of US stimuli led to a complete tumor regression in a breast cancer mouse model.
    Rizzitelli S; Giustetto P; Faletto D; Delli Castelli D; Aime S; Terreno E
    J Control Release; 2016 May; 230():57-63. PubMed ID: 27049069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An acoustic/thermo-responsive hybrid system for advanced doxorubicin delivery in tumor treatment.
    Zhang L; Zhang S; Chen H; Liang Y; Zhao B; Luo W; Xiao Q; Li J; Zhu J; Peng C; Zhang Y; Hong Z; Wang Y; Li Y
    Biomater Sci; 2020 Apr; 8(8):2202-2211. PubMed ID: 32100739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.
    Yu M; Lee C; Wang M; Tannock IF
    Cancer Sci; 2015 Oct; 106(10):1438-47. PubMed ID: 26212113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
    Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
    J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.